Risk of kidney failure and death associated with target-dose (vs. below-target-dose) RAS inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based reassessment of subgroup findings. - Raman VK; Vargas JD; Moore HJ; Wu WC; Patel SS; Zhang S; Morgan CJ; Lam PH; Heidenreich PA; Lu F; Ahmed AA; Fonarow GC; et al. (The American journal of medicine, 2026)